Your browser doesn't support javascript.
loading
p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas.
Redman, A M; Johnson, J S; Dally, R; Swartz, S; Wild, H; Paulsen, H; Caringal, Y; Gunn, D; Renick, J; Osterhout, M; Kingery-Wood, J; Smith, R A; Lee, W; Dumas, J; Wilhelm, S M; Housley, T J; Bhargava, A; Ranges, G E; Shrikhande, A; Young, D; Bombara, M; Scott, W J.
Affiliation
  • Redman AM; Department of Chemistry Research, Bayer Research Center, Pharmaceutical Division, West Haven, CT 06516, USA. aniko.redman.b@bayer.com
Bioorg Med Chem Lett ; 11(1): 9-12, 2001 Jan 08.
Article in En | MEDLINE | ID: mdl-11140741
Inhibitors of the MAP kinase p38 are potentially useful for the treatment for osteoporosis, arthritis, and other inflammatory diseases. A series of thienyl, furyl, and pyrrolyl ureas has been identified as potent p38 inhibitors, displaying in vitro activity in the nanomolar range.
Subject(s)
Search on Google
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Osteoporosis / Arthritis / Urea / Mitogen-Activated Protein Kinases / Enzyme Inhibitors Type of study: Prognostic_studies Limits: Humans Language: En Journal: Bioorg Med Chem Lett Journal subject: BIOQUIMICA / QUIMICA Year: 2001 Type: Article Affiliation country: United States
Search on Google
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Osteoporosis / Arthritis / Urea / Mitogen-Activated Protein Kinases / Enzyme Inhibitors Type of study: Prognostic_studies Limits: Humans Language: En Journal: Bioorg Med Chem Lett Journal subject: BIOQUIMICA / QUIMICA Year: 2001 Type: Article Affiliation country: United States